Micromet’s Experimental Cancer Drug Shows Promise in Leukemia Patients

by Kathy Jones on  June 11, 2011 at 5:34 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Maryland-based pharmaceutical company, Micromet's experimental cancer drug has been found to reduce the number of cancer cells in over 75 percent of leukemia patients and the company has said that it will be conducting a larger Phase II study soon.
 Micromet’s Experimental Cancer Drug Shows Promise in Leukemia Patients
Micromet’s Experimental Cancer Drug Shows Promise in Leukemia Patients

The drug, known as Blinatumomab, was found to have reduced the number of cancer cells to undetectable levels in nine of the 12 patients who had severe form of leukemia. The drug works by priming the T-cells in the body to directly attack the cancer cells.

The company said that it will be conducted a Phase II study with 25 patients suffering from acute lymphoblastic leukemia (ALL) and who had relapsed following chemotherapy treatment.

Commenting on the results of the initial study, lead researcher Max Topp said, "These results are particularly striking relative to the fact that the majority of enrolled patients had characteristics typically associated with a dismal outlook."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Leukemia Cancer and Homeopathy Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive